Zunera Tahir1, Arthur Kavanaugh2. 1. Division of Rheumatology, Allergy and Immunology, University of California, San Diego, US. 2. Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla CA, 92037,US.
Abstract
BACKGROUND: Golimumab (GOL) is a tumor necrosis factor inhibitor that is used for various types of inflammatory arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This article is a systematic review of the evidence for the efficacy and safety of golimumab in inflammatory arthritides, specifically RA, PsA and AS. METHODS: We conducted a search of randomized controlled trails in MEDLINE [PubMed], CENTRAL, Embase, and Current Controlled Trials databases (ClinicalTrials.gov) through 2017 for studies that evaluated golimumab in inflammatory arthritides. We focused on pivotal, phase III trials for this review of the safety and efficacy of the drug. However, as some important information is not available in detail in publications from the phase III studies, additional individual studies pertaining to antidrug antibodies were also included. RESULTS: A total of 12, randomized, double-blind, placebo-controlled studies were included in this review of literature. Two trials focused on the GOL response in the PsA population, four trials focused on the GOL response in the AS population, and five trials focused on the GOL response in the RA population. Additional studies that evaluated autodrug antibodies produced in patients using GOL were also included. CONCLUSION: Golimumab was found to be clinically effective and also have a good safety profile in the treatment of RA, PsA, and AS based on data available from large studies.
BACKGROUND: Golimumab (GOL) is a tumor necrosis factor inhibitor that is used for various types of inflammatory arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This article is a systematic review of the evidence for the efficacy and safety of golimumab in inflammatory arthritides, specifically RA, PsA and AS. METHODS: We conducted a search of randomized controlled trails in MEDLINE [PubMed], CENTRAL, Embase, and Current Controlled Trials databases (ClinicalTrials.gov) through 2017 for studies that evaluated golimumab in inflammatory arthritides. We focused on pivotal, phase III trials for this review of the safety and efficacy of the drug. However, as some important information is not available in detail in publications from the phase III studies, additional individual studies pertaining to antidrug antibodies were also included. RESULTS: A total of 12, randomized, double-blind, placebo-controlled studies were included in this review of literature. Two trials focused on the GOL response in the PsA population, four trials focused on the GOL response in the AS population, and five trials focused on the GOL response in the RA population. Additional studies that evaluated autodrug antibodies produced in patients using GOL were also included. CONCLUSION: Golimumab was found to be clinically effective and also have a good safety profile in the treatment of RA, PsA, and AS based on data available from large studies.
Authors: Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; Zhenhua Xu; John Han; Peter Taylor Journal: Arthritis Rheum Date: 2010-04
Authors: Paul Emery; Roy M Fleischmann; Larry W Moreland; Elizabeth C Hsia; Ingrid Strusberg; Patrick Durez; Peter Nash; Eric Jason B Amante; Melvin Churchill; Won Park; Bernardo Antonio Pons-Estel; Mittie K Doyle; Sudha Visvanathan; Weichun Xu; Mahboob U Rahman Journal: Arthritis Rheum Date: 2009-08
Authors: Atul Deodhar; John D Reveille; Diane D Harrison; Lilianne Kim; Kim Hung Lo; Jocelyn H Leu; Elizabeth C Hsia Journal: J Rheumatol Date: 2017-12-15 Impact factor: 4.666
Authors: Atul Deodhar; Jürgen Braun; Robert D Inman; Désirée van der Heijde; Yiying Zhou; Stephen Xu; Chenglong Han; Benjamin Hsu Journal: Ann Rheum Dis Date: 2014-11-11 Impact factor: 19.103
Authors: Michael E Weinblatt; Rene Westhovens; Alan M Mendelsohn; Lilianne Kim; Kim Hung Lo; Shihong Sheng; Lenore Noonan; Jiandong Lu; Zhenhua Xu; Jocelyn Leu; Daniel Baker; Clifton O Bingham Journal: Ann Rheum Dis Date: 2013-09-03 Impact factor: 19.103
Authors: C T Ritchlin; A Kavanaugh; D D Gladman; P J Mease; P Helliwell; W-H Boehncke; K de Vlam; D Fiorentino; O Fitzgerald; A B Gottlieb; N J McHugh; P Nash; A A Qureshi; E R Soriano; W J Taylor Journal: Ann Rheum Dis Date: 2008-10-24 Impact factor: 19.103
Authors: E C Keystone; M C Genovese; L Klareskog; E C Hsia; S T Hall; P C Miranda; J Pazdur; S-C Bae; W Palmer; J Zrubek; M Wiekowski; S Visvanathan; Z Wu; M U Rahman Journal: Ann Rheum Dis Date: 2008-12-09 Impact factor: 19.103
Authors: Manuel Pombo-Suarez; Carlos Sanchez-Piedra; Blanca Garcia-Magallón; Ana Pérez-Gómez; Sara Manrique-Arija; Raquel Martín-Doménech; María Colazo; Cristina Campos; José Campos; Javier Del Pino-Montes; Maria J Arteaga; Luis Cea-Calvo; Federico Díaz-González; Juan J Gómez-Reino Journal: Clin Rheumatol Date: 2021-04-27 Impact factor: 2.980
Authors: Juan J Alegre-Sancho; Xavier Juanola; José M Rodríguez-Heredia; Javier Manero; Ignacio Villa-Blanco; Ana Laiz; María J Arteaga; Luis Cea-Calvo; Carlos M González Journal: Medicine (Baltimore) Date: 2021-04-02 Impact factor: 1.817